Ripretinib
- Generic Name
- Ripretinib
- Brand Names
- Qinlock
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21BrFN5O2
- CAS Number
- 1442472-39-0
- Unique Ingredient Identifier
- 9XW757O13D
- Background
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.
- Indication
Ripretinib is indicated to treat adults diagnosed with advanced gastrointestinal stromal tumor (GIST) who have had prior therapy with at least 3 kinase inhibitors, including with imatinib.
- Associated Conditions
- Advanced Gastrointestinal Stromal Tumor (GIST)
Ripretinib (QINLOCK®) According to Current SmPC
- Conditions
- GIST - Gastrointestinal Stromal Tumor
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT06619275
- Locations
- 🇩🇪
Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05957367
- Locations
- 🇺🇸
University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT05734105
- Locations
- 🇮🇹
U.O.C. Oncologia Medica, Palermo, Italy
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
- Conditions
- Gastrointestinal Stromal Tumors
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Peking University
- Target Recruit Count
- 308
- Registration Number
- NCT05697107
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05132738
- Locations
- 🇨🇳
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Registration Number
- NCT05080621
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- Conditions
- Gastrointestinal Stromal Tumor(GIST)
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT04633122
- Locations
- 🇨🇳
The 4th Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳The Cancer Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST
- Conditions
- GIST - Gastrointestinal Stromal Tumor
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04530981
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT04282980
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
- Conditions
- GIST - Gastrointestinal Stromal Tumor
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Registration Number
- NCT04148092
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.